135 related articles for article (PubMed ID: 29043987)
1. Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
Jennane S; El Haddad M; Mahtat EM; Doghmi K; Mikdame M
Ann Biol Clin (Paris); 2017 Dec; 75(6):713-714. PubMed ID: 29043987
[No Abstract] [Full Text] [Related]
2. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A
J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971
[No Abstract] [Full Text] [Related]
3. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
[No Abstract] [Full Text] [Related]
4. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
[TBL] [Abstract][Full Text] [Related]
5. First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Schroeder T; Kobbe G
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1703-4. PubMed ID: 26277403
[No Abstract] [Full Text] [Related]
6. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
7. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
8. Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
Yee KW; Brandwein J; Schimmer AD; Gupta V; Del Bel R; Xu W; Minden MD; Schuh AC
Br J Haematol; 2014 Jul; 166(2):303-6. PubMed ID: 24650042
[No Abstract] [Full Text] [Related]
9. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I
Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231
[No Abstract] [Full Text] [Related]
10. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Kantarjian HM
J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
[No Abstract] [Full Text] [Related]
11. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
13. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Inoue A; Kawakami C; Takitani K; Tamai H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
[TBL] [Abstract][Full Text] [Related]
14. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
[No Abstract] [Full Text] [Related]
15. Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.
Nakamura Y; Matsuguma M; Tokunaga Y; Yamamoto K; Tanaka M; Tanaka Y; Yujiri T; Tanizawa Y
Intern Med; 2017; 56(10):1199-1202. PubMed ID: 28502936
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
Kamiya T; Nakazato T
Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
[No Abstract] [Full Text] [Related]
17. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
[No Abstract] [Full Text] [Related]
18. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
19. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
[No Abstract] [Full Text] [Related]
20. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
